Olmesartan/Amlodipine Hct (Olmesartan Medoxomil, Hydrochlorothiazide, Amlodipine Besilate)

Olmesartan/Amlodipine Hct is used in the management of hypertension, acting on several complementary pathways to lower blood pressure.

• Hypertension: provides additive blood‑pressure reduction by combining an ARB, a calcium‑channel blocker and a thiazide diuretic.
• Resistant hypertension: offers an option when monotherapy does not achieve target pressures.
• Cardiovascular risk reduction: assists in lowering the risk of stroke and myocardial infarction associated with uncontrolled hypertension.

• The combination tablet works by three mechanisms: olmesartan medoxomil blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction; amlodipine besilate inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation; and hydrochlorothiazide promotes renal sodium and water excretion, decreasing plasma volume. Together these actions produce a synergistic reduction in systemic vascular resistance and blood volume, lowering arterial pressure.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Headache: mild to moderate intensity.
• Peripheral edema: swelling of the ankles or lower legs.
• Dizziness or light‑headedness, especially after the first doses.
• Fatigue: general feeling of tiredness.
• Increased urination: due to the diuretic component.
• Flushing: transient warmth or redness of the skin.

Serious or Rare Side Effects

• Angio‑edema: rapid swelling of the face, lips, tongue or throat.
• Severe hypotension: marked drop in blood pressure causing fainting.
• Electrolyte disturbances: significant changes in potassium or sodium levels.
• Acute kidney injury: sudden decline in renal function.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Blood dyscrasias: rare blood‑cell abnormalities such as agranulocytosis.

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters.

• Renal function: evaluate baseline creatinine and eGFR, adjust if impaired.
• Electrolytes: check serum potassium and sodium, especially with the thiazide component.
• Hepatic status: use caution in patients with liver disease.
• Pregnancy: avoid use; teratogenic risk associated with ARBs and thiazides.
• Elderly patients: start at lower dose and monitor for orthostatic hypotension.
• Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and light.

Olmesartan/Amlodipine Hct may interact with several drug classes; careful review of a patient’s medication list is essential.

Major Interactions (Avoid)

• Aliskiren: concurrent use with ARBs can increase risk of renal impairment and hyperkalemia.
• Potassium‑saving diuretics or supplements: may cause dangerous hyperkalemia.
• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): can raise amlodipine levels.

Moderate Interactions (Monitor Closely)

• NSAIDs: may blunt antihypertensive effect and affect renal function.
• Lithium: increased lithium levels and risk of toxicity.
• Other antihypertensives: additive blood‑pressure lowering may require dose adjustment.